Illinois Rybelsus Stomach Paralysis Lawsuit (2024 Update)

Quick Summary

• Stomach paralysis due to Rybelsus is a serious issue affecting many individuals in Illinois. Rybelsus is part of a broader category of diabetes drugs that have been linked to severe gastrointestinal issues. Like other diabetes medications, Rybelsus has been associated with significant health risks.
• This article provides a comprehensive overview of the Illinois Rybelsus stomach paralysis lawsuit, detailing your legal options, recent case updates, and the steps you can take to seek justice and compensation.
• If you or a loved one has faced complications from Rybelsus, Schmidt & Clark, LLP, we are here to support you. With a strong track record in plaintiff representation, our mission is to help you achieve the justice and compensation you deserve.

How S&C Can Help With Your Claim?

S&C can help with your claim by leveraging its expertise in pharmaceutical litigation. It assists clients through the intricate process of filing a lawsuit for stomach paralysis induced by prescription drugs like Rybelsus.

With a team of seasoned trial attorneys dedicated to helping plaintiffs in these lawsuits, S&C provides nationwide legal assistance to those in need. We can also provide:

• Free case evaluation to determine claim viability.
• Comprehensive legal representation throughout the process.
• Support and legal strategies to secure fair compensation.

Rybelsus Stomach Paralysis Lawsuit

Rybelsus lawsuits are currently causing a stir in the legal sphere, with the primary focus on the severe gastrointestinal side effects induced by the medication. Plaintiffs are alleging that Novo Nordisk, the manufacturer, failed to provide adequate warnings about the potential risks, including stomach paralysis and other digestive issues.

Similar to the Ozempic lawsuit, the Rybelsus lawsuits also center on allegations of inadequate warnings about severe gastrointestinal risks.

These lawsuits highlight the significant impact of Rybelsus on individuals’ lives, leading to severe stomach problems and long-term health complications.

In March 2024, a leadership committee was suggested to handle the escalating number of Rybelsus lawsuits. This move indicates the possibility of a federal multidistrict litigation (MDL) being established in the future.

This process would consolidate individual lawsuits into one court for pre-trial proceedings without combining them into a single lawsuit. This process aims to streamline the legal proceedings and ensure a more efficient resolution for the plaintiffs.

Currently, there is no Rybelsus class action lawsuit in the United States. Legal action may be pursued individually. However, the ongoing litigation is closely monitored, with the potential for significant developments that could impact the course of these cases. As more individuals come forward with their stories and legal actions are taken, the fight for justice continues.

What Is Rybelsus?

According to EMA, Rybelsus is the brand name for semaglutide, a prescription drug intended for the treatment of type 2 diabetes. When used alongside diet and exercise, it helps control blood sugar levels in adults [1].

The drug obtained FDA approval on September 20, 2019. This represented a noteworthy landmark as the inaugural oral GLP-1 treatment for type 2 diabetes. Rybelsus, which comes in 7 and 14 mg tablets, is produced by the Danish pharmaceutical company Novo Nordisk.

In January 2023, the FDA approved an update that allows Rybelsus to be used as a first-line treatment for type 2 diabetes, further broadening its application. Despite its primary use in controlling blood sugar, Rybelsus has also found an off-label use as a weight loss drug for weight management, although it is not FDA-approved for weight loss.

Compared to prescribed Ozempic, which is also used for diabetes and weight management, Rybelsus offers an oral alternative but shares similar benefits and risks.

This off-label use has contributed to its widespread adoption but also increased the risk of severe side effects, making it essential to consider the potential risks and benefits of weight loss drugs like Rybelsus.

How Does Rybelsus Work?

Rybelsus works by consisting of the active ingredient semaglutide, emulating the function of GLP-1, a hormone generated in the gut following food consumption. When GLP-1 is released, it signals the pancreas to secrete insulin, helping the body absorb glucose from the blood into cells for energy or storage.

Additionally, as a GLP-1 receptor agonist, Rybelsus inhibits the secretion of glucagon, a hormone that increases blood sugar levels, thereby preventing excessive glucose release from the liver.

By stimulating insulin secretion and reducing glucagon production, Rybelsus helps regulate blood sugar levels. Moreover, Rybelsus slows down gastric emptying, which regulates the rate at which nutrients enter the bloodstream and prevents sudden spikes in blood sugar levels after meals.

Although these mechanisms are advantageous for managing type 2 diabetes, they carry substantial risks as well. The risks associated with these mechanisms include:

• Slower gastric emptying, which can lead to severe gastrointestinal issues
• Impact on stomach muscles, potentially causing gastroparesis or stomach paralysis
• Increased risk of gastroparesis
• Ongoing lawsuits related to the use of Rybelsus

Rybelsus Side Effects and Symptoms

While effective in controlling blood sugar levels, Rybelsus is linked to several severe gastrointestinal issues.

According to the UBC Faculty of Medicine, one of the most concerning side effects is gastroparesis or stomach paralysis. Another serious side effect is severe abdominal pain, which can indicate a medical condition or a potential consequence of taking the medication [2].

This condition, where food sits too long in the stomach due to delayed gastric emptying, can lead to long-term health complications such as malnutrition-related disorders and an inability to digest and pass food properly.

According to Healthline, other severe side effects associated with Rybelsus include [3]:

• Bowel obstructions
• Acid reflux
• Nausea
• Vomiting
• Abdominal pain
• Bloating

These adverse reactions can be debilitating, significantly impacting the quality of life of those affected. In some cases, the side effects can lead to more serious health complications, such as:

• Esophageal injury
• Deep vein thrombosis (DVT)
• Pancreatic cancer

Rybelsus FDA-Approval and Its Black Box Warning

Rybelsus, marking a debut as an oral GLP-1 treatment for type 2 diabetes, received FDA approval on September 20, 2019. This marks a significant advancement for individuals managing this condition.

This approval marked a significant advancement in diabetes treatment, offering an alternative to injectable medications. In January 2023, the FDA further expanded its use by approving Rybelsus as a first-line treatment for type 2 diabetes, reflecting its effectiveness in managing blood sugar levels.

Nonetheless, this approval was accompanied by grave warnings. Rybelsus carries a black box warning, the most stringent warning given by the FDA, due to studies showing an increased risk of thyroid cancer in lab animals.

This warning highlights the potential for severe medical complications, particularly for individuals with a family history of thyroid cancer or multiple endocrine neoplasia syndrome type 2, who are advised not to use the drug.

The black box warning is crucial for consumers, as it underscores the importance of being aware of the potential risks associated with Rybelsus. Despite its benefits in controlling blood sugar, the severity of the possible side effects necessitates careful consideration and consultation with healthcare providers before starting the medication.

Studies have found increased risks of gastrointestinal adverse events (biliary disease,2 pancreatitis,3 bowel obstruction,4 and gastroparesis5) in patients with diabetes – Mohit Sodhi, MSc1, Researcher at the Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

How Do You Qualify for a Rybelsus Stomach Paralysis Lawsuit?

To qualify for a Rybelsus stomach paralysis lawsuit, you must show that you have experienced severe side effects directly linked to the medication. This involves providing medical documentation confirming diagnoses such as gastroparesis, gallbladder cancer, ileus, or gastrointestinal blockage.

Proof of prescription and records of medical interventions, such as hospitalization or emergency room visits, are essential to strengthen your case. Additionally, a doctor’s testimony connecting your health condition to Rybelsus is crucial.

If you meet these criteria, consulting with an experienced attorney can help determine the viability of your claim and guide you through the process of seeking compensation.

The Status Of The Rybelsus Stomach Paralysis Litigation in Illinois

The progression of the Rybelsus stomach paralysis litigation in Illinois is ongoing, with numerous lawsuits highlighting the drug’s severe side effects.

Plaintiffs allege that Novo Nordisk did not adequately warn users of the risks associated with Rybelsus, particularly with off-label use. Reported injuries include stomach paralysis and other severe gastrointestinal issues.

The Rybelsus litigation is part of a broader trend of lawsuits, including Ozempic lawsuits, addressing severe gastrointestinal issues.

A multi-district litigation (MDL) has been established to manage the increasing number of cases related to Rybelsus-induced stomach paralysis. This MDL involves shared evidence discovery and pre-trial motions, aiming to streamline the legal process. Currently, 58 lawsuits have been filed against Novo Nordisk, with more expected to join the MDL.

Recent developments have seen significant progress. As of February 2024, lawsuits involving medications like Ozempic and Wegovy had been consolidated into an MDL. By March, 18 lawsuits had joined the MDL, increasing to 101 cases by May.

Following Judge Pratter’s death on June 6, 2024, the Rybelsus lawsuit was paused until Judge Karen Spencer Marston took over on June 8, 2024. New judicial orders were issued during the first status conference on June 17, 2024. A ‘Science Day’ is scheduled for June 14, 2024, to provide an overview of relevant medical and scientific issues.

Rybelsus Lawsuit Settlement Amounts in Illinois

Expected settlement amounts for grave injuries in Rybelsus lawsuits span between $400,000 and $700,000, contingent on the severity of the individual’s damages. These settlements aim to compensate for both economic and non-economic losses, including medical expenses, lost wages, and pain and suffering.

Economic losses can cover a wide range of expenses, from hospital bills to ongoing medical treatments and therapies. Non-economic damages, such as pain and suffering, recognize the emotional and physical toll that severe health complications can have on a person’s life.

Additionally, compensation might cover out-of-pocket expenses related to the treatment of side effects from Rybelsus.

The value of settlements in Rybelsus lawsuits varies based on individual cases and the extent of the injuries sustained. For those who have experienced significant health issues due to Rybelsus, pursuing a lawsuit can be a crucial step toward obtaining the financial support needed to manage their medical and personal needs.

Filing a Rybelsus Stomach Paralysis Lawsuit in Illinois

Navigating the legal process can be daunting, but having skilled legal representation can greatly enhance the likelihood of a favorable outcome.

Understanding the necessary steps to file a lawsuit and the importance of acting promptly is vital for those impacted by Rybelsus. Consulting with an experienced attorney can offer clarity and support, ensuring your rights are upheld and your case is managed effectively.

Legal Strategies and Challenges

Rybelsus lawsuits’ legal strategies typically concentrate on the drug labels’ failure to warn about grave injuries despite adverse effect reports sufficiently.

A significant approach is the use of differential diagnosis to establish causation for injuries, which involves evaluating all potential causes and ruling out unlikely ones to isolate the drug as a likely contributor.

Developing a plaintiff fact sheet detailing individual injuries is also a common strategy to streamline the discovery process in large-scale litigation.

One of the challenges in these lawsuits is the defendants’ attempts to limit tests to prove causation to overly restrictive methods.

Proving causation is critical and often requires comprehensive evidence gathering to support claims of inadequate warnings and resulting injuries. Establishing a failure to warn claim is pivotal, with plaintiffs arguing that the drug labels did not adequately communicate the severe risk of gastroparesis.

The plaintiffs’ legal strategy includes criticizing drug labels for not highlighting the severity of gastrointestinal side effects that could suggest chronic conditions. Overcoming these challenges requires a strong legal team capable of presenting a compelling case based on robust evidence and expert testimonies.

Types of Evidence To Present

Fortifying a Rybelsus lawsuit requires the presentation of diverse types of evidence, including:

• Medical records
• Prescription proof
• Records of emergency room visits and hospitalizations
• Documentation of missed work

Proof of prescription for Rybelsus is fundamental evidence in supporting a lawsuit, establishing a direct link between the medication and the adverse health effects experienced.

Medical records documenting emergency room visits and hospitalizations related to Rybelsus are crucial. These records illustrate the severity and impact on the individual’s health. Additionally, documentation of missed work due to side effects helps quantify the economic losses suffered by the plaintiff.

Comprehensive evidence is essential for building a strong case against Novo Nordisk. This evidence supports claims of inadequate warnings and demonstrates the extent of injuries and the resulting financial and personal impact on the affected individuals.

What Is the Statute of Limitations for a Rybelsus Lawsuit In Illinois?

The statute of limitations for a Rybelsus lawsuit in Illinois is typically two years, depending on the specifics of the case. Given the variations, it is crucial to consult with a lawyer knowledgeable in local laws to understand the specific deadlines applicable to your situation.

Related Articles:

• Arkansas Rybelsus Stomach Paralysis Lawsuit
• Louisiana Rybelsus Stomach Paralysis Lawsuit
• Florida Rybelsus Stomach Paralysis Lawsuit

See all related dangerous drug lawsuits our attorneys covered so far.

Get Your Free Consultation From Our Illinois Rybelsus Lawyers

The Schmidt & Clark, LLP law firm stands ready to assist you during these difficult times. If you or a loved one has experienced complications from a prescription medication like Rybelsus, reach out to us. Our team possesses extensive expertise in managing such cases and will guide you through the legal process.

We will explain your rights and evaluate your eligibility for a lawsuit regarding these complications. Receive a free case evaluation, and remember, we charge fees only if we win your case.

You can trust our dedication to your case as if you were a member of our own family. Contact us today for a thorough review of your concerns.

Reference:

1. https://www.ema.europa.eu/en/documents/product-information/rybelsus-epar-product-information_en.pdf
2. https://www.med.ubc.ca/news/weight-loss-drugs-linked-to-stomach-paralysis
3. https://www.healthline.com/health/drugs/rybelsus#side-effects